Journal of Oral Medicine and Pain

Korean Academy of Orofacial Pain and Oral Medicine (대한안면통증구강내과학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment Protocol for Secondary Burning Mouth Syndrome in Candida albicans- or Non-albicans-Positive Patients

  • Ju, Hye-Min (Department of Oral Medicine, Institute of Translational Dental Sciences, Pusan National University) ;
  • Jeong, Sung-Hee (Department of Oral Medicine, Institute of Translational Dental Sciences, Pusan National University) ;
  • Ahn, Yong-Woo (Department of Oral Medicine, Institute of Translational Dental Sciences, Pusan National University) ;
  • Jeon, Hye-Mi (Dental Clinic Center, Pusan National University Hospital) ;
  • Ok, Soo-Min (Department of Oral Medicine, Institute of Translational Dental Sciences, Pusan National University)
  • Received : 2022.08.25
  • Accepted : 2022.09.08
  • Published : 2022.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to propose an efficient treatment approach for infection with different candida species. Methods: Fifty-three patients who presented with a chief complaint of oral mucosal pain and exhibited positive candida culture findings were divided into two groups (Candida albicans and non-albicans). Pain, mucosal manifestations, salivary flow rates, durations of disease and treatment, and responses to treatment (nystatin and clonazepam) were investigated in both groups. Results: Patients in the C. albicans group exhibited more prominent clinical characteristics (erythematous lesions, tongue coatings, and hyperalgesia) than those in the non-albicans group. In total, 70% of patients in the non-albicans group showed no abnormalities in the oral mucosa. Patients in the C. albicans group showed increased resistance to nystatin treatment compared to those in the non-albicans group, especially with longer disease durations. The patients resistant to nystatin treatment showed positive responses to clonazepam. Conclusions: Patients with oral mucosal pain should be tested for the presence of Candida, even in the absence of mucosal abnormalities, especially those infected with non-albicans species. If no response to antifungal therapy is observed, treatment with clonazepam should be initiated, especially in patients infected with C. albicans.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2020R1F1A1049150).

References

  1. Riley JL 3rd, Gilbert GH, Heft MW. Orofacial pain symptom prevalence: selective sex differences in the elderly? Pain 1998;76:97-104. https://doi.org/10.1016/S0304-3959(98)00030-X
  2. Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 1999;28:350-354. https://doi.org/10.1111/j.1600-0714.1999.tb02052.x
  3. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003;14:275-291. https://doi.org/10.1177/154411130301400405
  4. Lopez-Jornet P, Camacho-Alonso F, Andujar-Mateos P, SanchezSiles M, Gomez-Garcia F. Burning mouth syndrome: an update. Med Oral Patol Oral Cir Bucal 2010;15:e562-e568.
  5. Gorsky M, Silverman S Jr, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome. An open study of 130 patients. Oral Surg Oral Med Oral Pathol. 1991;72:192-195. https://doi.org/10.1016/0030-4220(91)90162-6
  6. Vitkov L, Weitgasser R, Hannig M, Fuchs K, Krautgartner WD. Candida-induced stomatopyrosis and its relation to diabetes mellitus. J Oral Pathol Med 2003;32:46-50. https://doi.org/10.1034/j.1600-0714.2003.00020.x
  7. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed) 1988;296:1243-1246. https://doi.org/10.1136/bmj.296.6631.1243
  8. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996;7:182-187. https://doi.org/10.1097/00001648-199603000-00013
  9. Shinozaki S, Moriyama M, Hayashida JN, et al. Close association between oral Candida species and oral mucosal disorders in patients with xerostomia. Oral Dis 2012;18:667-672. https://doi.org/10.1111/j.1601-0825.2012.01923.x
  10. Hertel M, Schmidt-Westhausen AM, Strietzel FP. Local, systemic, demographic, and health-related factors influencing pathogenic yeast spectrum and antifungal drug administration frequency in oral candidiasis: a retrospective study. Clin Oral Investig 2016;20:1477-1486. https://doi.org/10.1007/s00784-015-1631-0
  11. Muadcheingka T, Tantivitayakul P. Distribution of Candida albicans and non-albicans Candida species in oral candidiasis patients: correlation between cell surface hydrophobicity and biofilm forming activities. Arch Oral Biol 2015;60:894-901. https://doi.org/10.1016/j.archoralbio.2015.03.002
  12. Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis 2014;33:673-688. https://doi.org/10.1007/s10096-013-2009-3
  13. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96. https://doi.org/10.1128/cmr.12.1.80
  14. Garcia Heredia M, Garcia SD, Copolillo EF, et al. [Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents]. Rev Argent Microbiol 2006;38:9-12. Spanish.
  15. Navazesh M, Kumar SK. Measuring salivary flow: challenges and opportunities. J Am Dent Assoc 2008;139 Suppl:35S-40S. https://doi.org/10.14219/jada.archive.2008.0353
  16. Villa A, Polimeni A, Strohmenger L, Cicciu D, Gherlone E, Abati S. Dental patients' self-reports of xerostomia and associated risk factors. J Am Dent Assoc 2011;142:811-816. https://doi.org/10.14219/jada.archive.2011.0269
  17. Heintze U, Birkhed D, Bjorn H. Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J 1983;7:227-238.
  18. Lalla RV, Patton LL, Dongari-Bagtzoglou A. Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies. J Calif Dent Assoc 2013;41:263-268. https://doi.org/10.1080/19424396.2013.12222301
  19. Rodriguez de Rivera Campillo E, Lopez-Lopez J, ChimenosKustner E. Response to topical clonazepam in patients with burning mouth syndrome: a clinical study. Bull Group Int Rech Sci Stomatol Odontol 2010;49:19-29.
  20. Amos K, Yeoh SC, Farah CS. Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study. J Orofac Pain 2011;25:125-130.
  21. Eliasson L, Birkhed D, Carlen A. Feeling of dry mouth in relation to whole and minor gland saliva secretion rate. Arch Oral Biol 2009;54:263-267. https://doi.org/10.1016/j.archoralbio.2008.09.001
  22. Murugesh J, Annigeri RG, Raheel SA, Azzeghaiby S, Alshehri M, Kujan O. Effect of yogurt and pH equivalent lemon juice on salivary flow rate in healthy volunteers- an experimental crossover study. Interv Med Appl Sci 2015;7:147-151. https://doi.org/10.1556/1646.7.2015.4.3
  23. Leal SC, Bittar J, Portugal A, Falcao DP, Faber J, Zanotta P. Medication in elderly people: its influence on salivary pattern, signs and symptoms of dry mouth. Gerodontology 2010;27:129-133. https://doi.org/10.1111/j.1741-2358.2009.00293.x
  24. Nakamura S, Okamoto MR, Yamamoto K, et al. The Candida species that are important for the development of atrophic glossitis in xerostomia patients. BMC Oral Health 2017;17:153. https://doi.org/10.1186/s12903-017-0449-3
  25. Parnanen P, Meurman JH, Samaranayake L, Virtanen I. Human oral keratinocyte E-cadherin degradation by Candida albicans and Candida glabrata. J Oral Pathol Med 2010;39:275-278. https://doi.org/10.1111/j.1600-0714.2009.00866.x
  26. Kaur R, Domergue R, Zupancic ML, Cormack BP. A yeast by any other name: Candida glabrata and its interaction with the host. Curr Opin Microbiol 2005;8:378-384. https://doi.org/10.1016/j.mib.2005.06.012
  27. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against Candida fungal infections. Nat Rev Immunol 2015;15:630-642. https://doi.org/10.1038/nri3897
  28. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 1995;115:1265-1275. https://doi.org/10.1111/j.1476-5381.1995.tb15035.x
  29. Imamura Y, Shinozaki T, Okada-Ogawa A, et al. An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives. J Oral Rehabil 2019;46:574-587. https://doi.org/10.1111/joor.12795
  30. Tantivitayakul P, Panpradit N, Maudcheingka T, Klaophimai A, Lapirattanakul J. Genotyping of Candida albicans and Candida dubliniensis by 25S rDNA analysis shows association with virulence attributes in oral candidiasis. Arch Oral Biol 2019;97:18-24. https://doi.org/10.1016/j.archoralbio.2018.10.006
  31. Spiering MJ, Moran GP, Chauvel M, et al. Comparative transcript profiling of Candida albicans and Candida dubliniensis identifies SFL2, a C. albicans gene required for virulence in a reconstituted epithelial infection model. Eukaryot Cell 2010;9:251-265. https://doi.org/10.1128/EC.00291-09
  32. Luo G, Samaranayake LP. Candida glabrata, an emerging fungal pathogen, exhibits superior relative cell surface hydrophobicity and adhesion to denture acrylic surfaces compared with Candida albicans. APMIS 2002;110:601-610. https://doi.org/10.1034/j.1600-0463.2002.1100902.x
  33. Zhang Y, Li X, Yuan J, et al. Prognostic factors for visual acuity in patients with Leber's hereditary optic neuropathy after rAAV2-ND4 gene therapy. Clin Exp Ophthalmol 2019;47:774-778. https://doi.org/10.1111/ceo.13515
  34. Munro G, Hansen RR, Mirza NR. GABAA receptor modulation: potential to deliver novel pain medicines? Eur J Pharmacol 2013;716:17-23. https://doi.org/10.1016/j.ejphar.2013.01.070
  35. Al-Zuhairy A, Sindrup SH, Andersen H, Jakobsen J. A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy. J Peripher Nerv Syst 2019;24:64-71. https://doi.org/10.1111/jns.12311
  36. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH. Multifocal motor neuropathy. Lancet Neurol 2005;4:309-319. https://doi.org/10.1016/S1474-4422(05)70074-0
  37. Cats EA, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010;75:818-825. https://doi.org/10.1212/WNL.0b013e3181f0738e